CJC-1295 DAC: The Science of GH Regulation

CJC-1295 DAC (Drug Affinity Complex) is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), designed to enhance endogenous growth hormone (GH) secretion. It has become a focal point of research due to its extended half-life and controlled release properties. This article provides a scientific overview of CJC-1295 DAC’s mechanism, molecular design, and laboratory relevance.

Mechanism and Biochemistry

binds to the GHRH receptor on pituitary somatotroph cells, triggering the secretion of GH in a pulsatile manner. The incorporation of the DAC component extends its half-life to several days, making it more stable than traditional GHRH analogues. This sustained release profile allows researchers to study long-term GH modulation and its metabolic impacts with greater consistency.

Peptide Synthesis and Stability

Synthesised through solid-phase peptide synthesis (SPPS), CJC-1295 DAC undergoes rigorous purification via HPLC and structural verification using MS. These steps ensure that the peptide’s molecular integrity aligns with pharmaceutical-grade standards. Stability studies demonstrate that the DAC modification enhances resistance to enzymatic degradation, prolonging its bioavailability for research applications.

Research Applications

Laboratory investigations have utilised CJC-1295 DAC to study the dynamics of GH release, muscle protein synthesis, and cellular metabolism. Preclinical trials have indicated its potential in improving lean muscle mass, enhancing recovery, and modulating IGF-1 (Insulin-like Growth Factor 1) production. These findings contribute to understanding how GH-related pathways influence tissue regeneration and metabolic health.

Conclusion

CJC-1295 DAC continues to serve as a critical tool for studying hormonal regulation mechanisms. With its stable pharmacokinetic profile and potent GH-releasing capacity, it remains one of the most valuable GHRH analogues available for scientific research.